NASDAQ · GMAB
Genmab A/S
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
Loading market information…
NASDAQ · TGTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TG Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
TG Therapeutics, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of $0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow TG Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | $0.03-83.33% vs estimate | $120.86M-9.94% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | $0.15+87.5% vs estimate | $108.19M-0.57% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | $0.02-33.33% vs estimate | $83.88M-15.09% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $80.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
$10.23-$0.29 (-2.76%)
Corvus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.04% below the high.
$1.49-$0.13 (-8.02%)
ADC Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.08% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$1.50-$0.02 (-1.32%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.65% below the high.
$2.68+$0.01 (+0.37%)
Adagene Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.74% below the high.
